Država: Sjedinjene Američke Države
Jezik: engleski
Izvor: NLM (National Library of Medicine)
MIDODRINE HYDROCHLORIDE (UNII: 59JV96YTXV) (MIDODRINE - UNII:6YE7PBM15H)
American Health Packaging
MIDODRINE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE 2.5 mg
ORAL
PRESCRIPTION DRUG
Midodrine hydrochloride tablets, USP are indicated for the treatment of symptomatic orthostatic hypotension (OH). Because midodrine hydrochloride tablets, USP can cause marked elevation of supine blood pressure (BP > 200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion and lifestyle alterations. The indication is based on midodrine hydrochloride tablet, USP's effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride tablets, USP principally improved ability to perform life activities, have not been established. Further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets, USP. After initiation of treatment, midodrine hydrochloride tablets, USP should be continue
Midodrine Hydrochloride Tablets, USP, for oral administration, are available as 2.5 mg White, round, flat-faced, bevelled edge, debossed “ E ” over “40” on one side and bisected on the other side and supplied as: Unit dose packages of 100 (10 x 10) NDC 68084-240-01 5 mg Reddish-orange, round, flat-faced, bevelled edge, debossed “ E ” over “43” on one side and bisected on the other side and supplied as: Unit dose packages of 100 (10 x 10) NDC 68084-241-01 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. FOR YOUR PROTECTION: Do not use if blister is torn or broken. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Abbreviated New Drug Application
MIDODRINE HCL- MIDODRINE HYDROCHLORIDE TABLET AMERICAN HEALTH PACKAGING ---------- MIDODRINE HYDROCHLORIDE TABLETS, USP 8024001/1017 RX ONLY WARNING BECAUSE MIDODRINE HYDROCHLORIDE TABLETS CAN CAUSE MARKED ELEVATION OF SUPINE BLOOD PRESSURE, IT SHOULD BE USED IN PATIENTS WHOSE LIVES ARE CONSIDERABLY IMPAIRED DESPITE STANDARD CLINICAL CARE. THE INDICATION FOR USE OF MIDODRINE HYDROCHLORIDE TABLETS IN THE TREATMENT OF SYMPTOMATIC ORTHOSTATIC HYPOTENSION IS BASED PRIMARILY ON A CHANGE IN A SURROGATE MARKER OF EFFECTIVENESS, AN INCREASE IN SYSTOLIC BLOOD PRESSURE MEASURED ONE MINUTE AFTER STANDING, A SURROGATE MARKER CONSIDERED LIKELY TO CORRESPOND TO A CLINICAL BENEFIT. AT PRESENT, HOWEVER, CLINICAL BENEFITS OF MIDODRINE HYDROCHLORIDE TABLETS, PRINCIPALLY IMPROVED ABILITY TO CARRY OUT ACTIVITIES OF DAILY LIVING, HAVE NOT BEEN VERIFIED. DESCRIPTION Midodrine hydrochloride is a vasopressor/antihypotensive agent. Midodrine hydrochloride is an odorless, white, crystalline powder, soluble in water and sparingly soluble in methanol having a pKa of 7.8 (0.3% aqueous solution), a pH of 3.5 to 5.5 (5% aqueous solution) and a melting range of 200°C to 203°C. It is chemically described as: (1) Acetamide, 2-amino- _N_-[2-(2,5-dimethoxyphenyl)-2- hydroxyethyl]-monohydrochloride, (±)-; or (2) (±)-2-amino- _N_-(ß-hydroxy-2,5- dimethoxyphenethyl)acetamide monohydrochloride. Midodrine hydrochloride’s molecular formula is C H N O HCl, its molecular weight is 290.7 and its structural formula is: Each tablet for oral administration contains 2.5 mg, 5 mg or 10 mg of midodrine hydrochloride and the following inactive ingredients: pregelatinized starch (corn starch), microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate. In addition, the 5 mg tablets contain FD&C yellow No. 6 aluminum lake and FD&C red No. 40 aluminum lake and the 10 mg tablets contain FD&C blue No. 2 aluminum lake. CLINICAL PHARMACOLOGY 12 18 2 4 MECHANISM OF ACTION Midodrine hydrochloride forms an active metabolite, desglymidodrine, that is an Pročitajte cijeli dokument